Weight Management in Obese Cancer Patients During Curative Active Treatment
Launched by INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE · Jul 9, 2025
Trial Information
Current as of July 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a special weight management program can help people with obesity who are undergoing treatment for certain types of cancer (stage II-IV solid tumors). The study aims to see if following a personalized low-calorie, high-protein diet combined with guided home exercise and behavioral support is possible and helpful during cancer treatment. The hope is that managing weight in this way might improve overall health and treatment outcomes.
Adults aged 18 and older with a body mass index (BMI) of 30 or higher, who have recently been diagnosed with specific solid tumors and are starting cancer treatments like chemotherapy or radiation with the goal of cure, may be eligible. Participants need to live near Barcelona, have good overall health, and access to the internet for support. The program will last throughout their cancer treatment, which is expected to take at least three months. People with certain cancers, other serious health conditions, or those already in weight loss programs are not eligible. If you join, you can expect personalized diet and exercise guidance along with support to help you stick to the program safely during your cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age 18+) with pathologically confirmed malignant solid tumors, stage II-IV, elected for oncological treatment (chemo, radio, or both) with curative intend.
- • Expected oncological treatment time ≥ 3 months.
- • BMI ≥ 30 kg/m²
- • Resident in the Barcelona area up to the completion of cancer treatment.
- • ECOG Perfomance Status (PS) 0-1
- • Availability of internet access.
- Exclusion Criteria:
- • Patients with melanoma and brain tumours.
- • Surgery as the only treatment.
- * Tumour localizations with high risk of malnutrition (such as head and neck, upper gastrointestinal tract, or pancreatic cancer):
- • Pregnancy or breastfeeding
- • Another active malignancy
- • Current health or medical condition that affects weight status, e.g., untreated hyper- or hypothyroidism,etc
- • Pre-existing medical condition that precludes adherence to unsupervised exercise, e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, or unstable angina, heart attack, congestive heart failure or conditions that dictated hospitalization or oxygen within 6-months.
- • Unable to read or understand Spanish or Catalan
- • Enrolled in a weight loss program
- • Active suicidal ideation, anorexia, bulimia, binge eating disorder, current substance abuse or dependence (besides nicotine dependence)
- • Use of pacemaker or another electrical implanted device
- • History of bariatric (or LapBand) surgery, or considering or currently on a wait-list for bariatric or LapBand surgery
- • Patients with any concurrent medical or psychological condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
About Institut D'investigació Biomèdica De Bellvitge
The Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) is a leading biomedical research institute located in Bellvitge, Spain, dedicated to advancing medical knowledge and improving patient care through innovative research. Affiliated with the Bellvitge University Hospital and the University of Barcelona, IDIBELL focuses on a wide range of biomedical fields, including cancer, neuroscience, and regenerative medicine. The institute fosters collaboration among researchers, clinicians, and industry partners to facilitate the translation of scientific discoveries into clinical applications, ultimately aiming to enhance health outcomes and contribute to the development of groundbreaking therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
L'hospitalet De Llobregat, Barcelona, Spain
Patients applied
Trial Officials
Lorena Arribas, PhD, MsC, RD
Principal Investigator
Catalan Institute of Oncology (ICO-Hospitalet). Bellvitge Biomedical Research Institute (IDIBELL)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported